Quince Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Quince Therapeutics reported disappointing Phase 3 trial results for eDSP, leading to the discontinuation of its development and a pivot towards exploring strategic alternatives, including a potential reverse merger.
NASDAQ
Quince Therapeutics reported increased net losses and R&D expenses for Q3 2025, raising substantial doubt about its ability to continue as a going concern despite clinical trial progress and recent financing.
NASDAQ
Quince Therapeutics reports progress in its Phase 3 A-T trial and secures a strategic partnership, but faces substantial doubt about its ability to continue as a going concern.
NASDAQ
10-Q: Quince Therapeutics Reports Q1 2025 Results, Faces Going Concern Uncertainty Amidst Phase 3 Trial
Quince Therapeutics reports a net loss of $15.03 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to insufficient funding.
NASDAQ
10-Q: Quince Therapeutics Reports Third Quarter 2024 Results, Provides Update on EryDex Clinical Trial
Quince Therapeutics' Q3 2024 report highlights progress in the EryDex Phase 3 trial, alongside financial updates and a waiver of a key debt covenant.
NASDAQ
Quince Therapeutics reported its second quarter 2024 results, including a significant goodwill impairment charge, while also highlighting progress in its Phase 3 clinical trial for EryDex.
NASDAQ
Quince Therapeutics reports a net loss of $11.1 million for the first quarter of 2024, while progressing its EryDex clinical program and preparing for a Phase 3 trial.